Posted on Authorea 12 Jan 2022 | The copyright holder is the author/funder. All rights reserved. No reuse without permission. | https://doi.org/10.22541/au.164202786.62577319/v1 | This a preprint and has not been peer reviewed. Data may be preliminary.

Mepolizumab – therapeutic strategy for a paediatric patient with eosinophilic granulomatosis with polyangiitis

Lota Ozola[1], Elīna Aleksejeva[1], Diāna Stoldere[1], Ineta Grantiņa[1], Zane Dāvidsone[1], Ruta Šantere[1], Ieva Cīrule[1], and Alvils Krams[2]

[1]Bērnu klīniskā universitātes slimnīca
[2]Rīgas Austrumu klīniskā universitātes slimnīca

January 12, 2022

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome) is classified as an anti-neutrophil cytoplasmic antibody (ANCA)-associated small vessel vasculitis. It is a multisystem disorder and can affect every organ system. EGPA is a rare disease, with an estimated prevalence of 1/70,000–100,000 in Europe. As its onset usually occurs in adulthood, data from paediatric patients are limited. We present here a very rare practical EGPA clinical case involving a paediatric patient. Presently, data on mepolizumab usage in paediatric patients are limited, with only a few case reports published.

Hosted file

`Case report. ERJ.labots_CSE_Edited_CA. DS. 11.01.docx` available at https://authorea.com/users/455230/articles/552589-mepolizumab-therapeutic-strategy-for-a-paediatric-patient-with-eosinophilic-granulomatosis-with-polyangiitis